TNGX
Tango Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Tango Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−4.81%
vs ±11.4% implied · ×0.42
shaded = implied · ▲▼ = realized
| Manager | Value | % base | |
|---|---|---|---|
| RTW | $434.5M | 6.49% | +4.51% |
| BlackRockindex-like | $388.8M | 5.80% | +42.19% |
| FMR | $385.5M | 5.75% | +24.50% |
| Farallon | $383.8M | 5.73% | +34.95% |
| Boxer | $340.0M | 5.07% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| RTW | $434.5M | 6.49% | +4.51% |
| BlackRockindex-like | $388.8M | 5.80% | +42.19% |
| FMR | $385.5M | 5.75% | +24.50% |
| Farallon | $383.8M | 5.73% | +34.95% |
| Boxer | $340.0M | 5.07% | 0.00% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Tango Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Tango Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Tango Therapeutics, Inc.
23.24
pre 23.24 +6.79%
Bull1
Bear2
—
—
Largest filed tie
—
Tall tick = annual report · Source: EDGAR
Expected move
Inputs8Q avg ±9.5%·×1.13·fair
straddle ±15.7%
spot 23.17exp Nov 20ATM strike 23ATM straddle 4.28IV 108%